title: Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate).
abstract: Osteoporosis is an important feature of osteogenesis imperfecta (OI). So far, no effective medical treatment is available. We treated three boys with severe OI type III and vertebral deformities for 5-7 years with continuous oral administration of the bisphosphonate, olpadronate. Treatment resulted in a decreased number of bone fractures, an increased calcification of the long bones and an amelioration of vertebral shape. No side-effects were encountered.
  
  
  CONCLUSIONS
  These preliminary but long-term observations suggest that the bisphosphonate olpadronate may be a useful treatment for patients with OI and vertebral fractures. Bisphosphonates may be promising drugs for children with OI.
authors.affiliation: Department of Paediatrics, University Hospital Leiden, The Netherlands.
authors.forename: E A
authors.initials: EA
authors.lastname: Landsmeer-Beker
authors.forename: G G
authors.initials: GG
authors.lastname: Massa
authors.forename: P D
authors.initials: PD
authors.lastname: Maaswinkel-Mooy
authors.forename: J J
authors.initials: JJ
authors.lastname: van de Kamp
authors.forename: S E
authors.initials: SE
authors.lastname: Papapoulos
mesh_terms: D001827:Body Height / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D002648:Child; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008134:Long-Term Care; D008297:Male; D010013:Osteogenesis Imperfecta / Q000188:drug therapy*
chemical_list: D004164:Diphosphonates; C055774:olpadronic acid